Abstract Number: 2133 • 2012 ACR/ARHP Annual Meeting
Relationship Between Clinical Response and Radiographic Outcomes in Patients with Moderate Rheumatoid Arthritis
Background/Purpose: Clinical evidence has established the importance of early, intensive treatment of rheumatoid arthritis (RA) to decrease disease activity and prevent joint damage.1 The objective…Abstract Number: 398 • 2012 ACR/ARHP Annual Meeting
Basal Metabolic Rate As an Indicator of Rheumatoid Arthritis Disease Activity and Predictor of Remission
Background/Purpose: The role of body mass index (BMI) in rheumatoid arthritis (RA) disease activity and response to treatment has been difficult to determine.1 As a…Abstract Number: 2002 • 2012 ACR/ARHP Annual Meeting
Randomized Clinical Trial in Pediatric Rheumatology: Are Parents and Patients in Equipoise?
Background/Purpose: It is an ethical requirement for setting up a randomized controlled trial (RCT) that the physician-investigator must have genuine uncertainty about the therapeutic options.…Abstract Number: 386 • 2012 ACR/ARHP Annual Meeting
Costs of Tumor Necrosis Factor Blockers Per Treated Rheumatoid Arthritis Patient Using Real-World Drug Data in a US Managed Care Population
Background/Purpose: Etanercept (ETN), adalimumab (ADA), and infliximab (INF) are FDA-approved tumor necrosis factor (TNF)-blocker treatments for moderate to severe rheumatoid arthritis (RA) and are commonly…Abstract Number: 1829 • 2012 ACR/ARHP Annual Meeting
Cost of Etanercept, Adalimumab, and Infliximab in Patients with Rheumatoid Arthritis with Employer Provided Health Insurance
Background/Purpose: Tumor Necrosis Factor Inhibitors (TNFi) are the mainstay of treatment for rheumatoid arthritis (RA) in patients with moderate to severe disease. The three most…Abstract Number: 368 • 2012 ACR/ARHP Annual Meeting
Impact of Etanercept-Methotrexate Therapy On Patient-Reported Outcomes in Rheumatoid Arthritis Patients with up to 12 Months of Symptoms
Background/Purpose: Patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) are critical in evaluating RA treatment effects on function and health-related quality of life (HR-QoL).…Abstract Number: 1641 • 2012 ACR/ARHP Annual Meeting
When Can Biological Therapy Be Resumed in Patients with Rheumatic Conditions Who Develop Tuberculosis Infection During Tumour Necrosis Factors Antagonists Therapy? Study Based On the Biobadaser Data Registry
Background/Purpose: Tuberculosis infection (TI) is one of the most serious adverse events related to tumour necrosis factor (TNF) antagonists. According to the current treatment guidelines…Abstract Number: 275 • 2012 ACR/ARHP Annual Meeting
Pediatric Rheumatology Practitioners Experience with Biologics in Juvenile Dermatomyositis: Survey Results
Background/Purpose: Biologic therapy is increasingly prescribed in rheumatologic disorders. Juvenile dermatomyositis (JDM), the most common inflammatory myopathy in children, can be challenging to manage in…
- « Previous Page
- 1
- …
- 7
- 8
- 9